Targeted LYmphatic and MIcrovessel Treatments in metabolic-DISease HFpEF
| Ebba Brakenhielm
INSERM, Rouen Institute for Research and Innovation in Biomedicine, France
Marc Van Bilsen, Maastricht University, Maastricht, The Netherlands
Anna Ratajska, Medical University of Warsaw, Poland
Elizabeth Jones, Ku Leuven, Leuven, Belgium
Arantxa Gonzalez Miqeo Foundation for Applied Medical Research, Pamplona, Spain
Heart Failure (HF) represents a serious health challenge, with an estimated 6.5 million patients suffering from HF in the European Union. LYMIT-DIS is aimed at improved diagnosis, prognosis, and the development of new treatments for HF, focusing on HF with preserved Ejection Fraction (HFpEF). This type of HF with diastolic cardiac dysfunction, affects more than 50% of HF patients, notably women, and is linked to metabolic syndrome, an increasingly common condition characterized by insulin resistance, abdominal obesity, dyslipidemia, and hypertension.The overall objective of LYMIT-DIS is to forward our understanding of the mechanisms involved in the cardiac diastolic dysfunction in HFpEF, with the aim to identify and evaluate innovative treatments.